科学公共图书馆
期刊
会议
图书
作者:... Sean Emery , David A. Cooper , Mark A. Boyd
来源:[J].PLOS ONE(IF 3.73), 2013, Vol.8 (2)PLOS
摘要:There is an urgent need to improve the evidence base for provision of second-line antiretroviral therapy (ART) following first-line virological failure. This is particularly the case in Sub-Saharan Africa where 70% of all people living with HIV/AIDS (PHA) reside. The aim of this ...
作者:Mark A. Boyd , Matthew G. Law ...
来源:[J].PLOS ONE(IF 3.73), 2014, Vol.9 (6)PLOS
摘要:Regimens sparing RATE (ritonavir, abacavir, tenofovir, efavirienz) agents might have better long-term safety. We conducted a feasibility exercise to assess the potential for a randomised trial evaluating RATE-sparing regimens.;;Observational.;;We first calculated RATE-sparin...
作者:Mark A. Boyd , Nagalingeswaran Kumarasamy ...
来源:[J].PLOS ONE(IF 3.73), 2015, Vol.10 (2)PLOS
摘要:To determine the durability over 96 weeks of safety and efficacy of lopinavir/ritonavir (LPV/r) and raltegravir (RAL) which was demonstrated to have non-inferior efficacy relative to a regimen of LPV/r with nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) (C...
作者:Mark A. Boyd , Evy Yunihastuti ...
来源:[J].PLOS ONE(IF 3.73), 2013, Vol.8 (6)PLOS
摘要:In the Asia-Pacific region many countries have adopted the WHO’s public health approach to HIV care and treatment. We performed exploratory analyses of the factors associated with first major modification to first-line combination antiretroviral therapy (ART) in resource-ric...
作者:... Samuel Ferret , David A. Cooper , Mark A. Boyd
来源:[J].PLOS ONE(IF 3.73), 2013, Vol.8 (10)PLOS
摘要:To compare changes over 48 weeks in body fat, lipids, Metabolic Syndrome and cardiovascular disease risk between patients randomised 1∶1 to lopinavir/ritonavir (r/LPV) plus raltegravir (RAL) compared to r/LPV plus 2–3 nucleoside/nucleotide reverse transcriptase inhibitors (N...
作者:Mark A. Boyd , Amanda Mocroft ...
来源:[J].PLOS Medicine(IF 16.269), 2017, Vol.14 (11)PLOS
摘要:The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study has developed predictive risk scores for cardiovascular disease (CVD) and chronic kidney disease (CKD, defined as confirmed estimated glomerular filtration rate [eGFR] ≤ 60 ml/min/1.73 m2) event...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×